InMed Pharmaceuticals (INM) Accounts Payables (2020 - 2026)

InMed Pharmaceuticals has reported Accounts Payables for 7 years, with the latest figure at $225051.0 in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 84.04% year-over-year to $225051.0; the trailing twelve-month figure through Mar 2026 stood at $225051.0 (down 84.04% YoY), and the FY2025 full-year result was $277856.0, down 83.2% from the prior year.
• Accounts Payables for Q1 2026 stood at $225051.0, up from $166752.0 in the prior quarter.
• The five-year high for Accounts Payables was $2.4 million in Q3 2022, with the low at $166752.0 in Q4 2025.
• Historically, Accounts Payables has averaged $1.1 million across 5 years, with a median of $1.2 million in 2022.
• The largest YoY upside for Accounts Payables was 250.12% in 2025 against a maximum downside of 87.84% in 2025.
• InMed Pharmaceuticals' Accounts Payables stood at $1.1 million in 2022, then climbed by 12.41% to $1.3 million in 2023, then grew by 6.49% to $1.4 million in 2024, then slumped by 87.84% to $166752.0 in 2025, then soared by 34.96% to $225051.0 in 2026.
• The last three Accounts Payables figures came in at $225051.0 (Q1 2026), $166752.0 (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.